An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.
A 19-year-old female with Diffuse Alopecia was advised by a dermatologist to use vitamin supplements, a hair serum, and antifungal drops, leading to some improvement. Other users suggested treatments like minoxidil, microneedling, and consulting a different dermatologist for further advice.
The user is experiencing hair loss and is using finasteride while addressing low ferritin and copper levels. They are concerned about continued hair shedding and are advised to correct vitamin deficiencies and wait for finasteride results after 12 months.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
Koshine 826 (Pyrilutamide) is being used by several users to address hair loss, with mixed results on shedding and side effects. Some users report reduced shedding and no side effects, while others experience increased shedding and potential issues with libido and erectile dysfunction.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The user experienced hair repigmentation and attributes improvements in hair and overall health to a carnivore diet, Boron, and Selenium supplementation. They stopped using finasteride after 20 years, noticed increased testosterone and libido, and observed hair regrowth with RU58841.
The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.
A 16-year-old diagnosed with male pattern baldness (MPB) was prescribed hair vitamins, vitamin D, a non-ketoconazole shampoo, and redenysl + serum, with a suggestion for GFC or IHRF treatments. Some users recommended minoxidil, ketoconazole, and derma stamping, while others advised against certain treatments until the age of 18.
The post humorously discusses an exaggerated hair loss treatment regimen including minoxidil, finasteride, microneedling, and "demon blood." Replies joke about the regimen and suggest alternative sources for "demon blood."
The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.
The user experienced excessive bleeding during microneedling after consuming caffeine and THC, and is unsure if they should continue with the same routine. They are seeking advice on whether the bleeding is a cause for concern.
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.
RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
Loose-Message9596 has been experiencing hair loss for 3-4 years, initially due to low ferritin and vitamin D levels, and has tried treatments like vitamins, System 4, and PRP therapy. They are considering starting finasteride and minoxidil but are unsure due to their relatively low DHT level of 425.
How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.
Oral supplementation of Nicotinamide Mononucleotide (NMN) improves hair quality and appearance in middle-aged women. However, it may reduce total hair density, possibly due to seasonal shedding.
After suffering from hair loss and Seborrheic Dermatitis for three years with no improvement from various treatments, the individual found success with COQ10 and PQQ supplements, which led to new hair growth and a healthy scalp without flare-ups. They also plan to start additional supplements recommended by a dermatologist.
The user is experiencing hair loss, possibly due to androgenic alopecia or telogen effluvium, and is considering treatments like Minoxidil, Finasteride, or RU58841. They also mention potential iron deficiency and sleep deprivation as contributing factors.
Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.
The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.
A user improved their hair health by taking 50,000 IU of vitamin D3 weekly due to a deficiency. Others discussed the potential link between vitamin D and hair growth, with some sharing similar experiences and emphasizing the importance of monitoring vitamin D levels and consulting with doctors.
Excess sebum rich in cholesterol and triglycerides can lead to hair loss through inflammation, with treatments like Ciclopirox shampoo, Benzoyl Peroxide shampoo, and Clindamycin gel recommended for managing conditions like seborrheic dermatitis and folliculitis. Pioglitazone is suggested for Lichen Planopilaris, while Omega-3s and reducing processed foods may improve sebum quality, though genetic factors play a significant role.